Oxurion NV (OXUR.BR)
EUR 0.09
(-4.45%)
EUR 0.09
(-4.45%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -16.72 Million EUR | 39.88% |
| 2022 | -29.96 Million EUR | 19.94% |
| 2021 | -28.17 Million EUR | 2.21% |
| 2020 | -27.39 Million EUR | 18.46% |
| 2019 | -49.25 Million EUR | 4.81% |
| 2018 | -35.11 Million EUR | -36.99% |
| 2017 | 26.49 Million EUR | -1.42% |
| 2016 | -52.65 Million EUR | 14.11% |
| 2015 | -29.86 Million EUR | 30.63% |
| 2014 | -42.81 Million EUR | -234.39% |
| 2013 | 33.17 Million EUR | 6.51% |
| 2012 | 31.11 Million EUR | 227.7% |
| 2011 | -21.25 Million EUR | -83.55% |
| 2010 | -14.23 Million EUR | -0.89% |
| 2009 | -13.52 Million EUR | -206.76% |
| 2008 | 12.33 Million EUR | 178.9% |
| 2007 | -17.09 Million EUR | -78.59% |
| 2006 | -8.75 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.3 Million EUR | 0.0% |
| 2023 Q2 | -7.73 Million EUR | 0.0% |
| 2023 Q4 | -4.91 Million EUR | 0.0% |
| 2023 FY | - EUR | 39.88% |
| 2022 FY | - EUR | 19.94% |
| 2022 Q2 | -13.53 Million EUR | 0.0% |
| 2022 Q4 | -8.88 Million EUR | 0.0% |
| 2021 Q2 | -14.99 Million EUR | 0.0% |
| 2021 Q4 | -12.93 Million EUR | 0.0% |
| 2021 FY | - EUR | 2.21% |
| 2020 FY | - EUR | 18.46% |
| 2020 Q4 | -15.26 Million EUR | 0.0% |
| 2020 Q2 | -12.89 Million EUR | 0.0% |
| 2019 Q2 | -16.01 Million EUR | 0.0% |
| 2019 Q4 | -18.51 Million EUR | 0.0% |
| 2019 FY | - EUR | 4.81% |
| 2018 Q2 | -13.83 Million EUR | 0.0% |
| 2018 Q4 | -23.07 Million EUR | 0.0% |
| 2018 FY | - EUR | -36.99% |
| 2017 Q4 | -13.88 Million EUR | 0.0% |
| 2017 FY | - EUR | -1.42% |
| 2017 Q2 | -13.05 Million EUR | 0.0% |
| 2016 Q4 | -15.43 Million EUR | 0.0% |
| 2016 Q2 | -11.13 Million EUR | 0.0% |
| 2016 FY | - EUR | 14.11% |
| 2015 FY | - EUR | 30.63% |
| 2015 Q4 | -15.17 Million EUR | 0.0% |
| 2015 Q2 | -15.75 Million EUR | 0.0% |
| 2014 Q4 | -24.23 Million EUR | 0.0% |
| 2014 Q2 | -20.34 Million EUR | 0.0% |
| 2014 FY | - EUR | -234.39% |
| 2013 Q2 | 57.69 Million EUR | 0.0% |
| 2013 Q4 | -24.52 Million EUR | 0.0% |
| 2013 FY | - EUR | 6.51% |
| 2012 Q1 | 7.78 Million EUR | 0.0% |
| 2012 FY | - EUR | 227.7% |
| 2012 Q4 | 8.52 Million EUR | 9.5% |
| 2012 Q2 | 7.78 Million EUR | 0.0% |
| 2012 Q3 | 7.78 Million EUR | 0.0% |
| 2011 Q4 | 7.78 Million EUR | 246.54% |
| 2011 Q1 | -5.31 Million EUR | 0.0% |
| 2011 Q2 | -5.31 Million EUR | 0.0% |
| 2011 FY | - EUR | -83.55% |
| 2011 Q3 | -5.31 Million EUR | 0.0% |
| 2010 FY | - EUR | -0.89% |
| 2010 Q2 | -3.32 Million EUR | 0.0% |
| 2010 Q1 | -3.32 Million EUR | 0.0% |
| 2010 Q3 | -3.32 Million EUR | 0.0% |
| 2010 Q4 | -5.31 Million EUR | -59.95% |
| 2009 Q1 | -3.29 Million EUR | 0.0% |
| 2009 FY | - EUR | -206.76% |
| 2009 Q3 | -3.29 Million EUR | 0.0% |
| 2009 Q2 | -3.29 Million EUR | 0.0% |
| 2009 Q4 | -3.32 Million EUR | -0.89% |
| 2008 Q4 | -3.29 Million EUR | -208.09% |
| 2008 FY | - EUR | 178.9% |
| 2008 Q1 | 3.04 Million EUR | 0.0% |
| 2008 Q2 | 3.04 Million EUR | 0.0% |
| 2008 Q3 | 3.04 Million EUR | 0.0% |
| 2007 Q3 | -3.9 Million EUR | 0.0% |
| 2007 Q4 | 3.04 Million EUR | 177.92% |
| 2007 FY | - EUR | -78.59% |
| 2007 Q2 | -3.9 Million EUR | 0.0% |
| 2007 Q1 | -3.9 Million EUR | 0.0% |
| 2006 Q4 | -3.9 Million EUR | -77.94% |
| 2006 FY | - EUR | 0.0% |
| 2006 Q3 | -2.19 Million EUR | 0.0% |
| 2006 Q2 | -2.19 Million EUR | 0.0% |
| 2006 Q1 | -2.19 Million EUR | 0.0% |
| 2005 Q4 | -2.19 Million EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Nicox S.A. | -16.23 Million EUR | -3.024% |
| European Medical Solutions | 59 Thousand EUR | 28454.237% |
| FERMENTALG | -10.51 Million EUR | -59.172% |
| argenx SE | -199.5 Million EUR | 91.615% |
| BioSenic S.A. | -6.79 Million EUR | -146.16% |
| Celyad Oncology SA | -7.76 Million EUR | -115.497% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | -11.676% |
| Onward Medical N.V. | -35.23 Million EUR | 52.52% |
| PHAXIAM Therapeutics S.A. | -22.93 Million EUR | 27.043% |
| Financière de Tubize SA | 184.57 Thousand EUR | 9163.721% |
| UCB SA | 1.26 Billion EUR | 101.318% |